Top

Published in:

01-01-2012

Targeting Angiogenesis in Gastroesophageal Cancer: Industry-Sponsored Trials are not the Answer

Author: Sarah K. Thompson

Published in: World Journal of Surgery | Issue 1/2012

Excerpt

Angiogenesis is a dynamic process essential for tumor growth. Maeda et al. first reported its association with poor prognosis in gastric cancer in 1996 and, since then, there have been numerous similar studies examining various factors that mediate angiogenesis such as vascular endothelial growth factor (VEGF) and platelet-derived growth factor [1]. It is therefore surprising that a decade and a half later there is still no clear consensus on the role of antiangiogenic agents in the treatment of gastroesophageal cancer and, more importantly, recognition of the patient subset who are most likely to benefit from these expensive agents. …

Reinmuth N, Parikh AA, Ahmad SA et al (2003) Biology of angiogenesis in tumors of the gastrointestinal tract. Microsc Res Tech 60:199–207PubMedCrossRef

Liu YF, Guo S, Zhao R, et al (2011) Correlation of vascular endothelial growth factor expression with tumor recurrence and poor prognosis in patients with pN0 gastric cancer. World J Surg. doi:10.1007/s00268-011-1192-6

Thompson SK, Ruszkiewicz AR, Jamieson GG et al (2010) Isolated tumor cells in esophageal cancer: implications for the surgeon and the pathologist. Ann Surg 252:299–306PubMedCrossRef

Hurwitz H, Fehrenbacher L, Novotny W et al (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335–2342PubMedCrossRef

Ohtsu A, Shah MA, Van Cutsem E et al (2011) Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study. J Clin Oncol. doi:10.1200/JCO.2011.36.2236

Okines AF, Reynolds AR, Cunningham D (2011) Targeting angiogenesis in esophagogastric adenocarcinoma. Oncologist 16:844–858PubMedCrossRef

Bang YJ, Van Cutsem E, Feyereislova A et al (2010) Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376:687–697PubMedCrossRef

Chua TC, Merrett ND (2011) Clinicopathological factors associated with HER2-positive gastric cancer and its impact on survival outcomes: a systematic review. Int J Cancer. doi:10.1002/ijc.26292

Garcia-Alvarez A, Garcia-Albeniz X, Esteve J et al (2010) Cardiotoxicity of tyrosine-kinase-targeting drugs. Cardiovasc Hematol Agents Med Chem 8:11–21PubMedCrossRef

10.

Howick J (2011) Moving EBM forward. In: The philosophy of evidence-based medicine. Wiley-Blackwell, Oxford, pp 189–191

Title: Targeting Angiogenesis in Gastroesophageal Cancer: Industry-Sponsored Trials are not the Answer
Author: Sarah K. Thompson
Publication date: 01-01-2012
Publisher: Springer-Verlag
Published in: World Journal of Surgery / Issue 1/2012
Print ISSN: 0364-2313
Electronic ISSN: 1432-2323
DOI: https://doi.org/10.1007/s00268-011-1324-z

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Targeting Angiogenesis in Gastroesophageal Cancer: Industry-Sponsored Trials are not the Answer

Excerpt

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 1/2012

Primary Closure Following Laparoscopic Common Bile Duct Exploration Combined with Intraoperative Cholangiography and Choledochoscopy

The Dr. Bovary Syndrome (DBS)

Diagnosing Appendicitis at Different Time Points in Children with Right Lower Quadrant Pain: Comparison Between Pediatric Appendicitis Score and the Alvarado Score

Long-Term Outcome in Patients with Primary Hyperparathyroidism who Underwent Minimally Invasive Parathyroidectomy

Impact of Preoperative Thrombocytosis on the Survival of Patients with Primary Colorectal Cancer

Correlation of Vascular Endothelial Growth Factor Expression With Tumor Recurrence and Poor Prognosis in Patients With pN0 Gastric Cancer